Revive Therapeutics Ltd., a life sciences firm founded in 2012 and headquartered in Toronto, Canada, is focused on discovering and advancing treatments for uncommon diseases and infectious illnesses. The company maintains a pharmaceutical pipeline centered on cannabinoids, specifically targeting rare inflammatory conditions. Key developments in its therapeutic portfolio include: Bucillamine: Currently in Phase 3 clinical trials, it is being investigated for combating infectious diseases such as influenza and COVID-19. Psilocybin: This compound is in Phase 1 clinical studies for its potential in treating methamphetamine use disorder. Psilocin: The company is exploring its application for a range of mental health challenges, including depression, anxiety, bipolar disorder, bulimia, and anorexia nervosa. Cannabidiol (CBD): This is under investigation for its use in autoimmune hepatitis and for reducing ischemia and reperfusion injury that can occur after organ transplantation. Revive Therapeutics Ltd. also engages in several strategic research partnerships. These collaborations include an alliance with PharmaTher Inc. to develop psilocybin for cancer treatment and to identify new applications for other psychedelic compounds; a project with North Carolina State University to create a biosynthetic version of psilocybin through an enzymatic platform; a joint effort with the University of California, San Francisco, to assess Bucillamine's effectiveness against severe COVID-19; clinical research into psychedelics with the University of Health Sciences Antigua; and another collaboration with PharmaTher for the advancement of a psilocybin microneedle patch.